Dogwood Therapeutics (DWTX) Change in Cash (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Change in Cash of $6.7 million for Q1 2026, up 149.24% year-over-year from $2.7 million in Q1 2025, and up 285.99% quarter-over-quarter from -$3.6 million in Q4 2025.
Dogwood Therapeutics (DWTX) Change in Cash (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Change in Cash for 7 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 149.24% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at -$4.3 million (down 128.23% YoY), while the FY2025 annual figure was -$8.3 million, down 171.38% from the prior year.
- Change in Cash grew to $6.7 million in Q1 2026 per DWTX's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Change in Cash topped out at $13.0 million in Q4 2024 and bottomed at -$4.1 million in Q2 2025.
- Historically, Change in Cash has averaged -$37961.8 across 5 years, with a median of -$980364.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Cash surged 981.63% — and 2025, when it sank 747.19%.
- Dogwood Therapeutics' Change in Cash stood at -$2.8 million in 2022, then surged by 46.72% to -$1.5 million in 2023, then soared by 981.63% to $13.0 million in 2024, then tumbled by 127.83% to -$3.6 million in 2025, then soared by 285.99% to $6.7 million in 2026.
- Business Quant data shows DWTX's Change in Cash at $6.7 million in Q1 2026, -$3.6 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | -3.60 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 12.95 Mn |
| Sep 30, 2024 | -980,364.00 |
| Jun 30, 2024 | 640,651.00 |
| Mar 31, 2024 | -937,414.00 |
| Dec 31, 2023 | -1.47 Mn |
| Sep 30, 2023 | 195,989.00 |
| Jun 30, 2023 | -742,414.00 |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -2.76 Mn |
| Sep 30, 2022 | 2.09 Mn |
| Jun 30, 2022 | -3.66 Mn |
| Mar 31, 2022 | -2.66 Mn |
| Dec 31, 2021 | -5.18 Mn |
| Sep 30, 2021 | -2.65 Mn |
| Jun 30, 2021 | -2.75 Mn |